Video

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

Author(s):

Michael Atkins, MD,Evan Lipson, MD

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Related Videos
Elizabeth Buchbinder, MD
Michael A. Postow, MD
Matthew P. Deek, MD
Thach-Giao Truong, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Related Content
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
December 13th 2024

FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

RP1 Plus Nivolumab in Advanced Melanoma
November 22nd 2024

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy